Zhu S-Q, Wang Q-M, Xue A-Q, Zheng L-Y, Su Y-F, Yu A-Y
The Eye Hospital of Wenzhou Medical University, Wenzhou, China.
Eye (Lond). 2014 Nov;28(11):1310-4. doi: 10.1038/eye.2014.200. Epub 2014 Aug 15.
To study the safety and efficacy of posterior scleral reinforcement (PSR) combined with phakic intraocular lens (PIOLs) implantation for highly myopic amblyopia in children.
This study included eight highly myopic children (11 eyes) who failed in conventional therapy for amblyopia using various combination of spectacles, contact lenses, and intensive patching before enrollment into this study. They were treated sequentially with PSR and PIOL implantation, and were followed up for 3 years after surgery. Uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA) in LogMAR, spherical equivalent power (SE), and complications were evaluated.
Before surgery, the mean UCVA was 1.59±0.33, BCVA, 0.74±0.37, SE, -17.57±5.56D, the axial length (AL), 30.09±2.18 mm. After PSR, BCVA improved one line in three patients, the rest were unchanged, and AL was unchanged among all cases. Six eyes of three patients were implanted with an iris-claw PIOL and five eyes of five patients were implanted with a posterior PIOL. After completion of treatment, the mean UCVA was 0.44±0.21, BCVA 0.38±0.24, SE -0.54±0.74 D, and AL 30.35±2.29 mm. No patient experienced complications.
Combined PSR and PIOL implantation treatment for highly myopic amblyopia in children is safe and effective.
研究后巩膜加固术(PSR)联合有晶状体眼人工晶状体(PIOLs)植入治疗儿童高度近视性弱视的安全性和有效性。
本研究纳入8例高度近视儿童(11只眼),这些儿童在入组本研究前,使用眼镜、隐形眼镜和强化遮盖等多种组合进行常规弱视治疗均失败。他们先后接受了PSR和PIOL植入治疗,并在术后随访3年。评估未矫正视力(UCVA)、以最小分辨角对数(LogMAR)表示的最佳矫正视力(BCVA)、等效球镜度(SE)及并发症。
术前,平均UCVA为1.59±0.33,BCVA为0.74±0.37,SE为-17.57±5.56D,眼轴长度(AL)为30.09±2.18mm。PSR术后,3例患者的BCVA提高了一行,其余患者不变,所有病例的AL均未改变。3例患者的6只眼植入了虹膜爪型PIOL,5例患者的5只眼植入了后房型PIOL。治疗结束后,平均UCVA为0.44±0.21,BCVA为0.38±0.24,SE为-0.54±0.74D,AL为30.35±2.29mm。无患者出现并发症。
PSR联合PIOL植入治疗儿童高度近视性弱视安全有效。